Shariat SF - Search Results

1

Tissue-based molecular markers for bladder cancer.

Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. Barbieri CE, et al. Among authors: shariat sf. Minerva Urol Nefrol. 2010 Sep;62(3):241-58. Minerva Urol Nefrol. 2010. PMID: 20940694 Review.

2

Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis.

Djavan B, Lin V, Kaplan EP, Richier JC, Shariat S, Marberger M, McConnell JD. Djavan B, et al. J Urol. 1998 Nov;160(5):1658-62. J Urol. 1998. PMID: 9783926

3

Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.

Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2000 Nov 1;56(5):735-40. doi: 10.1016/s0090-4295(00)00756-1. Urology. 2000. PMID: 11068290

4

Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.

Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Andrews B, et al. Among authors: shariat sf. J Urol. 2002 Mar;167(3):1475-81. J Urol. 2002. PMID: 11832773

5

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Shariat SF, et al. J Urol. 2003 Mar;169(3):938-42. doi: 10.1097/01.ju.0000043638.89552.ed. J Urol. 2003. PMID: 12576817

6

Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.

Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Shariat SF, et al. Urology. 2003 Jun;61(6):1140-5. doi: 10.1016/s0090-4295(03)00236-x. Urology. 2003. PMID: 12809883

7

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.

Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP. Shariat SF, et al. J Urol. 2004 Feb;171(2 Pt 1):626-30. doi: 10.1097/01.ju.0000107826.78479.90. J Urol. 2004. PMID: 14713774

8

Survivin expression is associated with features of biologically aggressive prostate carcinoma.

Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Shariat SF, et al. Cancer. 2004 Feb 15;100(4):751-7. doi: 10.1002/cncr.20039. Cancer. 2004. PMID: 14770431 Free article.

9

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.

Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. Shariat SF, et al. J Clin Oncol. 2004 Mar 15;22(6):1014-24. doi: 10.1200/JCO.2004.03.118. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981102

10

The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.

Lotan Y, Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG. Lotan Y, et al. Among authors: shariat sf. J Urol. 2004 Jun;171(6 Pt 1):2209-14. doi: 10.1097/01.ju.0000127730.78973.fe. J Urol. 2004. PMID: 15126787

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,905 results

Search Page

Filters